Back to Stakeholders

Enterprise Intelligence

Quarterly psychedelic drug-development briefing

Compare indication activity, programme milestones, competitive intensity, and near-term catalysts. Q2 includes quarter-over-quarter changes against the published Q1 baseline.

Damona Pharmaceuticals is a biotechnology company developing small-molecule therapeutics for the cognitive deficits associated with depression and diseases of ageing. It raised a US$5.5 million seed round in 2022, co-led by the psychedelic-sector investor Noetic Fund.

Ecosystem

1 connection

Investors

Noetic Fund

Seed financing (co-led)

Sep 26, 2022

$5.5m seed round

Damona raises $5.5m seed financing

Quick Facts

Website
Visit